Doma Perpetual Capital Management LLC Has $28.63 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Doma Perpetual Capital Management LLC grew its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 71.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,000,761 shares of the company's stock after buying an additional 418,321 shares during the quarter. Pacira BioSciences comprises 13.3% of Doma Perpetual Capital Management LLC's holdings, making the stock its 3rd biggest position. Doma Perpetual Capital Management LLC owned about 2.17% of Pacira BioSciences worth $28,632,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter worth approximately $30,000. GAMMA Investing LLC lifted its position in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after acquiring an additional 932 shares during the last quarter. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences during the 2nd quarter worth $46,000. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences in the 2nd quarter worth $50,000. Finally, nVerses Capital LLC raised its position in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after purchasing an additional 1,600 shares during the period. Institutional investors own 99.73% of the company's stock.

Analyst Ratings Changes

PCRX has been the topic of several recent analyst reports. Raymond James downgraded Pacira BioSciences from an "outperform" rating to a "market perform" rating in a report on Monday, August 12th. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $10.00 price objective (down from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. StockNews.com lowered Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday. Finally, HC Wainwright dropped their price target on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $24.10.

Pacira BioSciences Stock Up 3.0 %

Shares of NASDAQ:PCRX traded up $0.42 during midday trading on Thursday, reaching $14.33. 625,564 shares of the company were exchanged, compared to its average volume of 907,963. The stock has a fifty day simple moving average of $16.06 and a two-hundred day simple moving average of $23.64. The firm has a market cap of $667.00 million, a PE ratio of 10.02 and a beta of 0.84. The company has a quick ratio of 5.70, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $178.02 million during the quarter, compared to the consensus estimate of $173.31 million. As a group, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.24 earnings per share for the current year.

Insider Activity

In other Pacira BioSciences news, insider Jonathan Slonin sold 2,836 shares of the firm's stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now owns 95,557 shares of the company's stock, valued at approximately $2,699,485.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Pacira BioSciences news, CEO Frank D. Lee purchased 8,264 shares of the company's stock in a transaction dated Monday, August 12th. The stock was purchased at an average price of $12.10 per share, with a total value of $99,994.40. Following the completion of the purchase, the chief executive officer now owns 107,784 shares of the company's stock, valued at $1,304,186.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jonathan Slonin sold 2,836 shares of the firm's stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the transaction, the insider now owns 95,557 shares of the company's stock, valued at $2,699,485.25. The disclosure for this sale can be found here. Over the last ninety days, insiders acquired 11,176 shares of company stock worth $136,240 and sold 4,281 shares worth $105,494. 6.40% of the stock is owned by company insiders.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.